Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,300 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,300 shares of the company’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the completion of the transaction, the director owned 1,193 shares in the company, valued at approximately $109,207.22. This trade represents a 52.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Guardant Health Price Performance

Shares of GH stock opened at $91.20 on Tuesday. The firm has a 50 day moving average price of $105.09 and a two-hundred day moving average price of $89.33. The company has a market capitalization of $11.96 billion, a PE ratio of -27.55 and a beta of 1.67. Guardant Health, Inc. has a 12-month low of $34.88 and a 12-month high of $120.74.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. The company’s revenue was up 39.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.62) earnings per share. As a group, research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Institutional Trading of Guardant Health

Institutional investors have recently modified their holdings of the stock. V Square Quantitative Management LLC bought a new position in shares of Guardant Health in the fourth quarter worth $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health during the fourth quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the fourth quarter worth about $35,000. Finally, Parallel Advisors LLC increased its holdings in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on GH. BTIG Research increased their price objective on Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Guggenheim boosted their target price on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Piper Sandler upped their price target on shares of Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. Wells Fargo & Company raised their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Finally, Evercore set a $110.00 price objective on shares of Guardant Health in a research note on Friday, February 20th. Twenty-one investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $122.57.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.